Hansoh Pharmaceutical Group Breaks Ground on Global R&D Headquarters in Zhangjiang Headquarters Park

Mar 30, 2024 11:38 CST Updated 11:38

Hansoh Pharma

Pharmaceutical Research, Production, and Sales

As one of the sub-events of the "2024 Shanghai Global Investment Promotion Conference" series – the Pudong Industrial Ecosystem Scenario Cooperation and Development Conference.Groundbreaking Ceremony for Hansoh Pharmaceutical Group's Global R&D Headquarters Held Today at Zhangjiang Headquarter Park

Hansoh Pharmaceutical Group Global R&D Headquarters Project Commences in Zhangjiang Headquarter Park

Rendering of Hansoh Pharmaceutical Group's Global R&D Headquarters Project

Hansoh Pharmaceutical Group's Global R&D Headquarters Project is located in Zhangjiang Headquarters Park, with a total construction area of approximately 90,000 square meters, encompassing facilities such as biolabs and pilot-scale units, chemical R&D laboratories, R&D offices, and integrated service buildings. The project will establish world-leading innovative drug R&D technology platforms, including antibody-drug conjugate (ADC) technology, artificial intelligence technology, proteolysis targeting chimera (PROTAC) technology, and peptide drug technology, while undertaking global R&D management functions. It will become the birthplace of cutting-edge scientific innovation and a technological highland for Hansoh Pharma.

Establishing a global R&D headquarters in Zhangjiang Science City is an important part of Hansoh Pharma's integration of global innovative resources and its firm advancement of an innovation-driven development strategy. It also represents a concrete manifestation of fostering new-quality productive forces that are high-tech, highly efficient, and high-quality, marking a solid step for Hansoh Pharma towards becoming a globally leading innovation-driven pharmaceutical enterprise.

Hansoh Pharma Executive Director AiFeng Lü stated: "We will rely on the superior biopharmaceutical innovation ecosystem in Pudong, connect with global innovative resources, and build our R&D headquarters into a world-class biopharmaceutical R&D hub to accelerate the development of China's biopharmaceutical industry."

Hansoh Pharma has always adhered to scientific innovation leadership, actively explored global biotechnology frontiers, and accelerated the R&D and transformation of innovative technologies and products. The company has established four R&D centers in Maryland, USA, as well as in Shanghai, Changzhou, and Lianyungang, China, with approximately 1,671 professional R&D staff members. Hansoh continues to increase its R&D investment, with a 2023 R&D expenditure accounting for about 20.8% of revenue. Over 30 innovative drug projects at various clinical stages are currently underway, involving more than 50 clinical trials, forming a robust and competitive R&D pipeline.

About Hansoh Pharma

Hansoh Pharma is a leading innovation-driven pharmaceutical company in China, with subsidiaries including Hansoh Pharmaceuticals, Changzhou Hengbang Pharmaceuticals, and Hansoh Biologics. It is committed to improving the quality of human life through continuous innovation, focusing on areas such as anti-tumor, anti-infective, central nervous system diseases, metabolic diseases, and autoimmune diseases. The company has consistently ranked among the top 100 global pharmaceutical enterprises and the top three best industrial enterprises in China's pharmaceutical R&D product lines for many years. It is a key national high-tech enterprise and a national technology innovation demonstration enterprise, and was listed on the Hong Kong Stock Exchange in June 2019.

Hansoh Pharma adheres to the leadership of scientific innovation, actively explores global biotechnology frontiers, and accelerates the research, development, and commercialization of innovative technologies and products. The company has a team of approximately 1,671 professional researchers and has established a comprehensive R&D system covering the entire process from cutting-edge information collection, compound design and screening, pharmacological and toxicological studies to clinical research. Additionally, it has created multiple national-level R&D institutions, including a National Enterprise Technology Center, a Postdoctoral Research Station, and a State Key Laboratory.

Hansoh Pharma possesses efficient capabilities in the discovery of innovative large-molecule and small-molecule drugs, with a research and development layout covering areas such as monoclonal antibodies, ADC drugs, siRNA, bispecific antibodies, and fusion protein products. By the end of 2023, the company had launched seven innovative drugs, all of which have been included in the national medical insurance directory, with innovative product revenue accounting for 67.9%.

Hansoh Pharma will continue to deepen its innovation-driven strategy, relying on a globalized innovation ecosystem. With the goal of meeting the urgent clinical needs of patients in China and around the world, it aims to explore and develop more innovative and effective drugs to improve the quality of human life.

Source: Hello Zhangjiang

Previous Review

Aerial Photography Captures Construction Sites! Multiple Projects in Zhangjiang Science City Underway →

2024-03-29

Progress on Major Projects in Zhangjiang Science City (Phase II of the High-End Medical Device Innovation and Production Base)

2024-03-28

Zhangjiang Science Hall Has "Lin Space"

2024-03-27